Stoke Therapeutics, Inc. (STOK) Earnings History
Annual and quarterly earnings data from 2017 to 2024
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 100.0% | -277.3% | -243.4% |
| 2023 | 100.0% | -1307.2% | -1192.5% |
| 2022 | 100.0% | -841.2% | -814.7% |
| 2021 | - | - | - |
| 2020 | - | - | - |
Download Data
Export STOK earnings history in CSV or JSON format
Free sign-in required to download data
Stoke Therapeutics, Inc. (STOK) Earnings Overview
As of March 1, 2026, Stoke Therapeutics, Inc. (STOK) reported trailing twelve-month net income of $41M, reflecting +0.3% year-over-year growth. The company earned $0.69 per diluted share over the past four quarters, with a net profit margin of -2.4%.
Looking at the long-term picture, STOK's historical earnings data spans multiple years. The company achieved its highest annual net income of -$6M in fiscal 2017.
Stoke Therapeutics, Inc. maintains positive profitability with a gross margin of 1.0%, operating margin of -2.8%, and net margin of -2.4%. The company continues to generate positive earnings from operations. View revenue history →
Compared to industry peers including ALNY ($314M net income, 0.1% margin), IONS (-$381M net income, -0.4% margin), ARWR ($202M net income, -0.0% margin), STOK has room to improve margins relative to the peer group. Compare STOK vs ALNY →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
8 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$89M | +15.0% | -$101M | $-1.65 | -243.4% | -277.3% |
| 2023 | -$105M | -3.6% | -$115M | $-2.38 | -1192.5% | -1307.2% |
| 2022 | -$101M | -17.8% | -$104M | $-2.60 | -814.7% | -841.2% |
| 2021 | -$86M | -64.2% | -$86M | $-2.34 | - | - |
| 2020 | -$52M | -61.6% | -$53M | $-1.56 | - | - |
| 2019 | -$32M | -158.2% | -$36M | $-1.59 | - | - |
| 2018 | -$13M | -125.3% | -$13M | $-0.53 | - | - |
| 2017 | -$6M | - | -$6M | $-0.24 | - | - |
See STOK's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs STOK Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare STOK vs AGIO
See how STOK stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is STOK growing earnings?
STOK EPS of $0.69 reflects slowing growth at +0.3%, below the 5-year CAGR of N/A. TTM net income is $41M. Expansion rate has moderated.
What are STOK's profit margins?
Stoke Therapeutics, Inc. net margin is -2.4%, with operating margin at -2.8%. Below-average margins reflect competitive or cost pressures.
How consistent are STOK's earnings?
STOK earnings data spans 2017-2024. The current earnings trend is +0.3% YoY. Historical data enables comparison across business cycles.